{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:21:17Z","timestamp":1789154477585,"version":"build-2803163510"},"reference-count":52,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Croatian Institute for transfusion medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Due to its rapid resistance development and ability to form biofilms, treatment of Pseudomonas aeruginosa infections is becoming more complicated by the day. Drug combinations may help reduce both resistance and biofilm formation. Methods: Using the microtiter plate assay, we investigated the in vitro inhibition of biofilm formation and the disruption of preformed biofilms in multidrug-resistant and extensively drug-resistant clinical isolates of P. aeruginosa in the presence of peak plasma levels of eight antipseudomonal antibiotics alone and in combination with fosfomycin: ceftazidime, piperacillin\/tazobactam, cefepime, imipenem, gentamicin, amikacin, ciprofloxacin and colistin. Results: Combination therapy was significantly superior to monotherapy in its inhibition of biofilm formation. The highest inhibition rates were observed for combinations with colistin, cefepime and ceftazidime. Conclusion: Our results support fosfomycin combination therapy as an enhanced prophylactic option. Moreover, combinations with \u03b2-lactam antibiotics and colistin demonstrated a more potent inhibition effect on biofilm formation than protein synthesis inhibitors.<\/jats:p>","DOI":"10.3390\/ph17060769","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T06:47:30Z","timestamp":1718174850000},"page":"769","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3936-6400","authenticated-orcid":false,"given":"Mia","family":"Slade-Vitkovi\u0107","sequence":"first","affiliation":[{"name":"Microbiology Department, Croatian Institute of Transfusion Medicine, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1775-0807","authenticated-orcid":false,"given":"Ivanka","family":"Batarilo","sequence":"additional","affiliation":[{"name":"Microbiology Department, Croatian Institute of Transfusion Medicine, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Bielen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Clinical Hospital Centre Zagreb, 10000 Zagreb, Croatia"},{"name":"Department of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0253-4028","authenticated-orcid":false,"given":"Gordana","family":"Maravi\u0107-Vlahovi\u010dek","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Bedeni\u0107","sequence":"additional","affiliation":[{"name":"Clinical Department for Clinical and Molecular Microbiology, Clinical Hospital Centre Zagreb, 10000 Zagreb, Croatia"},{"name":"Biomedical Research Center \u0160alata\u2014BIMIS, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zakhour, J., Sharara, S.L., Hindy, J.R., Haddad, S.F., and Kanj, S.S. (2022). Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101432"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Olivares, E., Badel-Berchoux, S., Provot, C., Pr\u00e9vost, G., Bernardi, T., and Jehl, F. (2020). Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02894"},{"key":"ref_3","first-page":"286","article-title":"In-vitro Effect of Imipenem, Fosfomycin, Colistin, and Gentamicin Combination against Carbapenem-resistant and Biofilm-forming Pseudomonas aeruginosa Isolated from Burn Patients","volume":"20","author":"Adibkia","year":"2021","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12223-008-0008-z","article-title":"Antibiotic synergy against biofilm-forming Pseudomonas aeruginosa","volume":"53","author":"Votava","year":"2008","journal-title":"Folia Microbiol."},{"key":"ref_5","first-page":"Doc17","article-title":"In vitro synergy of antibiotic combinations against planktonic and biofilm Pseudomonas aeruginosa","volume":"12","author":"Ghorbani","year":"2017","journal-title":"GMS Hyg. Infect. Control"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1590\/0001-3765201820160131","article-title":"Evaluation antibacterial and antibiofilm activity of the antimicrobial peptide P34 against Staphylococcus aureus and Enterococcus faecalis","volume":"90","author":"Costa","year":"2018","journal-title":"An. Acad. Bras. Cienc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1128\/AAC.00196-16","article-title":"Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections","volume":"60","author":"Rubio","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/apm.12673","article-title":"Antibiotic treatment of biofilm infections","volume":"125","author":"Ciofu","year":"2017","journal-title":"Apmis"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Penesyan, A., Paulsen, I.T., Gillings, M.R., Kjelleberg, S., and Manefield, M.J. (2020). Secondary Effects of Antibiotics on Microbial Biofilms. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.02109"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","article-title":"Fosfomycin: An old\u2014New antibiotic","volume":"18","author":"Raz","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"a025262","DOI":"10.1101\/cshperspect.a025262","article-title":"Fosfomycin: Mechanism and Resistance","volume":"7","author":"Silver","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/jac\/dkw115","article-title":"Clinically relevant concentrations of fosfomycin combined with polymyxin, B.; tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance","volume":"71","author":"Walsh","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","first-page":"8","article-title":"New microbiological aspects of fosfomycin","volume":"32","year":"2019","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ijantimicag.2009.08.013","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections Clinical signifi-cance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections","volume":"34","author":"Roussos","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2110-5820-1-30","article-title":"Colistin: Recent data on pharmacodynamics properties and clinical efficacy in critically ill patients","volume":"1","author":"Michalopoulos","year":"2011","journal-title":"Ann. Intensive Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/2049-632X.12015","article-title":"Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin\/tobramycin antibiotic combination","volume":"67","author":"Anderson","year":"2013","journal-title":"Pathog. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chai, D., Liu, X., Wang, R., Bai, Y., and Cai, Y. (2016). Efficacy of Linezolid and Fosfomycin in Catheter-Related Biofilm Infection Caused by Methicillin-Resistant Staphylococcus aureus. Biomed. Res. Int., 2016.","DOI":"10.1155\/2016\/6413982"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ftz022","DOI":"10.1093\/femspd\/ftz022","article-title":"Fosfomycin tromethamine activity on biofilm and intracellular bacterial communities produced by uropathogenic Escherichia coli isolated from patients with urinary tract infection","volume":"77","author":"Notejane","year":"2019","journal-title":"Pathog. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/jac\/dkv221","article-title":"In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa","volume":"70","author":"Walsh","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","article-title":"Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates","volume":"31","author":"Samonis","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, L., Di Luca, M., Tkhilaishvili, T., Trampuz, A., and Gonzalez Moreno, M. (2019). Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02522"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1128\/AAC.00372-10","article-title":"Efficacy of the Combination of Tobramycin and a Macrolide in an In Vitro Pseudomonas aeruginosa Mature Biofilm Model","volume":"54","author":"Nagant","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e01650-17","DOI":"10.1128\/AAC.01650-17","article-title":"Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms","volume":"62","author":"Morosini","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/dkp224","article-title":"Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model","volume":"64","author":"Cai","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","first-page":"209","article-title":"Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm","volume":"59","author":"Mikuniya","year":"2005","journal-title":"Acta Med. Okayama"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10156-007-0534-7","article-title":"Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model","volume":"13","author":"Mikuniya","year":"2007","journal-title":"J. Infect. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s10156-002-0186-6","article-title":"Role of fosfomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm","volume":"8","author":"Monden","year":"2002","journal-title":"J. Infect. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1128\/AAC.39.5.1038","article-title":"Combination Effect of Fosfomycin and Ofloxacin against Pseudomonas aeruginosa Growing in a Biofilm","volume":"39","author":"Kumon","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Su, T., He, J., Li, N., Liu, S., Xu, S., and Gu, L. (2020). A Rational Designed PslG with Normal Biofilm Hydrolysis and Enhanced Resistance to Trypsin-Like Protease Digestion. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00760"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/jac\/dkac142","article-title":"Activity of fosfomycin\/colistin combinations against planktonic and biofilm Gram-negative pathogens","volume":"77","author":"Boncompagni","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"106887","DOI":"10.1016\/j.ijantimicag.2023.106887","article-title":"Ceftolozane\/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity","volume":"62","author":"Agyeman","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1128\/AAC.03170-14","article-title":"Synergy of silver nanoparticles and aztreonam against Pseudomonas aeruginosa PAO1 biofilms","volume":"58","author":"Habash","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/pathogens2020288","article-title":"From in vitro to in vivo Models of Bacterial Biofilm-Related Infections","volume":"2","author":"Lebeaux","year":"2013","journal-title":"Pathogens"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/1120009X.2022.2108247","article-title":"In vitro killing of multidrug\/extensively drug-resistant Pseudomonas aeruginosa by fosfomycin alone or in combination with antipseudomonal antibiotics","volume":"35","author":"Bielen","year":"2023","journal-title":"J. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_36","first-page":"37","article-title":"Oral and intravenous fosfomycin in complicated urinary tract infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1600-0463.2007.apm_630.x","article-title":"Quantification of biofilm in microtiter plates: Overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci","volume":"115","author":"Hola","year":"2007","journal-title":"Apmis"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Liu, Y., Wu, L., Han, J., Dong, P., Luo, X., Zhang, Y., and Zhu, L. (2020). Inhibition of Biofilm Formation and Related Gene Expression of Listeria monocytogenes in Response to Four Natural Antimicrobial Compounds and Sodium Hypochlorite. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.617473"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1038\/s41598-020-66082-x","article-title":"Evaluation of anti-biofilm activity of acidic amino acids and synergy with ciprofloxacin on Staphylococcus aureus biofilms","volume":"10","author":"Warraich","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Bernal-Mercado, A., Vazquez-Armenta, F., Tapia-Rodriguez, M., Islas-Osuna, M., Mata-Haro, V., Gonzalez-Aguilar, G., and Ayala-Zavala, J.F. (2018). Comparison of single and combined use of catechin, protocatechuic, and vanillic acids as antioxidant and antibacterial agents against uropathogenic Escherichia coli at planktonic and biofilm levels. Molecules, 23.","DOI":"10.3390\/molecules23112813"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wickremasinghe, H., Yu, H.H., Azad, M.A.K., Zhao, J., Bergen, P.J., Velkov, T., and Li, J. (2021). Clinically relevant concentrations of polymyxin B and meropenem synergistically kill multidrug-resistant Pseudomonas aeruginosa and minimize biofilm formation. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040405"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jac\/dkx483","article-title":"Antibacterial activity of ceftolozane\/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa","volume":"73","author":"Monogue","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","unstructured":"FDA (2021, December 20). Ceptaz (Ceftazidime for Injection) [Internet], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/050646s014lbl.pdf."},{"key":"ref_44","unstructured":"FDA (2021, December 20). Primaxin (Imipenem and Cilastatin) for Injection, for Intravenous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050587s074lbl.pdf."},{"key":"ref_45","unstructured":"FDA (2021, December 20). Fresenius Kabi USA, LCC. Gentamicin Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/062366s033lbl.pdf."},{"key":"ref_46","unstructured":"FDA (2021, December 20). Amikacin Sulfate [Internet], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/64146AP.PDF."},{"key":"ref_47","unstructured":"Car, H. (2020). In Vitro Synergy and Postantibiotic Effect of Colistin Combinations with Meropenem and Vancomycin against Gram Negative Bacteria with Multiple Carbapenem Resistance Mechanisms. [Ph.D. Thesis, The Josip Juraj Strossmayer University of Osijek]."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clinthera.2008.01.015","article-title":"Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study","volume":"30","author":"Markou","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijid.2020.08.010","article-title":"Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study","volume":"100","author":"Moni","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"23347","DOI":"10.1038\/srep23347","article-title":"Attenuation of Pseudomonas aeruginosa biofilm formation by Vitexin: A combinatorial study with azithromycin and gentamicin","volume":"6","author":"Das","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s42770-020-00284-3","article-title":"Synergistic effects of pomegranate and rosemary extracts in combination with antibiotics against antibiotic resistance and biofilm formation of Pseudomonas aeruginosa","volume":"51","author":"Ahmed","year":"2020","journal-title":"Braz. J. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Shinde, S., Lee, L.H., and Chu, T. (2021). Inhibition of Biofilm Formation by the Synergistic Action of EGCG-S and Antibiotics. Antibiotics, 10.","DOI":"10.3390\/antibiotics10020102"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/6\/769\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:57:16Z","timestamp":1760108236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/6\/769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ph17060769"],"URL":"https:\/\/doi.org\/10.3390\/ph17060769","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]}}}